The Favorable Short‐Term Efficacy of Preexisting COPD for Extensive‐Stage Small‐Cell Lung Cancer Receiving Immunotherapy
Cancer Medicine · 2026-07 · 15 (7)
DOI: 10.1002/cam4.72124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 19.07.2026. Verfasst von Ya Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Life Science and Medicine, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of USTC, University of Sci…. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, Pulmonary Disease, Chronic Obstructive, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Anhui Province Health and Scientific Research Project, Research Project of the Anhui Provincial Department of Education.
Themen: COPD
Abstract (Originalsprache)
Background
Preexisting chronic obstructive pulmonary disease (COPD) is associated with favorable clinical efficacy in NSCLC patients undergoing immune checkpoint inhibitors (ICIs). But the impact of COPD comorbidities on SCLC patients that are receiving immunotherapy remains unclear.
Methods
Patients with extensive‐stage SCLC (ES‐SCLC) received carboplatin combined with etoposide (carboplatin‐etoposide, EC group) or durvalumab plus carboplatin‐etoposide (EC + PD‐L1 group) treatment as first line therapy were collected. In EC + PD‐L1 group, survival of patients with preexisting COPD and patients without preexisting COPD were further compared.
Results
A total of 120 ES‐SCLC patients who met the eligibility criteria were included in this study. The median overall survival (OS) and the progression‐free survival (PFS) were significantly longer in the EC + PD‐L1 group than in the EC group, with a HR of 0.37 (95% CI, 0.16–0.88; p = 0.001) and 0.42 (95% CI, 0.23–0.77; p < 0.001), respectively. We further stratified groups by COPD status in EC + PD‐L1 group and EC group. In EC + PD‐L1 group, PFS was significantly prolonged in COPD group compared with the non‐COPD group, with a HR of 0.57 (95% CI, 0.35–0.96; p = 0.018). The COPD group demonstrated a numerically higher objective response rate than the non‐COPD group, though the difference was not statistically significant ( p = 0.292). No OS benefit was found between the groups.
Conclusion
Preexisting COPD status may be associated with favorable clinical efficacy in ES‐SCLC patients undergoing ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Life Science and Medicine, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
- Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Junqiang Zhang
Förderung
- Anhui Province Health and Scientific Research Project
- Research Project of the Anhui Provincial Department of Education
Zitieren
APA
Chen, Y., Liu, H., & Zhang, J. (2026). The Favorable Short‐Term Efficacy of Preexisting COPD for Extensive‐Stage Small‐Cell Lung Cancer Receiving Immunotherapy. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72124
Vancouver
Chen Y, Liu H, Zhang J. The Favorable Short‐Term Efficacy of Preexisting COPD for Extensive‐Stage Small‐Cell Lung Cancer Receiving Immunotherapy. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72124
BibTeX
@article{Chen2026,
author = {Chen, Ya and Liu, Hongyu and Zhang, Junqiang},
title = {The Favorable Short‐Term Efficacy of Preexisting COPD for Extensive‐Stage Small‐Cell Lung Cancer Receiving Immunotherapy},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/cam4.72124}
}
EUVIMED